How does A069620's PE Ratio compare to its peers?

A069620 is good value based on its Price-To-Earnings Ratio (14.3x) compared to the peer average (30.2x).

How does A069620's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

A069620 is expensive based on its Price-To-Earnings Ratio (14.3x) compared to the KR Pharmaceuticals industry average (14.2x).

What is A069620's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A069620 is good value based on its Price-To-Earnings Ratio (14.3x) compared to the estimated Fair Price-To-Earnings Ratio (20x).

What is the Fair Price of A069620 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A069620 (₩129100) is trading below our estimate of [[fair value]] (₩315181.68)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Daewoong Pharmaceutical (KOSE:A069620) - Stock Price, News & Analysis

A069620 Stock Overview

Manufactures and sells pharmaceutical products in South Korea and internationally. More details

A069620 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	4/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 59% below our estimate of its fair value

Earnings are forecast to grow 14.63% per year

Earnings grew by 123.3% over the past year

Analysts in good agreement that stock price will rise by 53%

Risk Analysis

High level of non-cash earnings

Debt is not well covered by operating cash flow

Daewoong Pharmaceutical Co., Ltd Competitors

Chong Kun Dang Pharmaceutical

KOSE:A185750

₩1.2t

Caregen

KOSDAQ:A214370

₩1.1t

ST PharmLtd

KOSDAQ:A237690

₩1.7t

Daewoong

KOSE:A003090

₩854.6b

Price History & Performance

Summary of all time highs, changes and price drops for Daewoong Pharmaceutical
Historical stock prices
Current Share Price	₩129,100.00
52 Week High	₩164,400.00
52 Week Low	₩100,100.00
Beta	0
11 Month Change	-16.06%
3 Month Change	-11.70%
1 Year Change	18.44%
33 Year Change	-6.79%
5 Year Change	-2.57%
Change since IPO	974.24%

Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)

Nov 22

There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price

Nov 06

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Oct 15

Recent updates

Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)

Nov 22

There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price

Nov 06

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Oct 15

Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 13

Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings

Jul 24

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Jul 04

Shareholder Returns

	A069620	KR Pharmaceuticals	KR Market
7D	-1.5%	-3.1%	2.9%
1Y	18.4%	4.8%	-2.8%

Return vs Industry: A069620 exceeded the KR Pharmaceuticals industry which returned 4.8% over the past year.

Return vs Market: A069620 exceeded the KR Market which returned -2.8% over the past year.

Price Volatility

Is A069620's price volatile compared to industry and market?
A069620 volatility
A069620 Average Weekly Movement	7.0%
Pharmaceuticals Industry Average Movement	5.2%
Market Average Movement	5.6%
10% most volatile stocks in KR Market	11.6%
10% least volatile stocks in KR Market	2.7%

Stable Share Price: A069620 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A069620's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1945	1,715	Chang-Jae Lee	www.daewoong.com

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices.

Daewoong Pharmaceutical Co., Ltd Fundamentals Summary

How do Daewoong Pharmaceutical's earnings and revenue compare to its market cap?
A069620 fundamental statistics
Market cap	₩1.49t
Earnings (TTM)	₩103.57b
Revenue (TTM)	₩1.42t

14.3x

P/E Ratio

1.0x

P/S Ratio

Is A069620 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A069620 income statement (TTM)
Revenue	₩1.42t
Cost of Revenue	₩692.09b
Gross Profit	₩724.54b
Other Expenses	₩620.96b
Earnings	₩103.57b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	9.00k
Gross Margin	51.15%
Net Profit Margin	7.31%
Debt/Equity Ratio	64.6%

How did A069620 perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

7%

Payout Ratio

A069620 Stock Overview

Rewards

Risk Analysis

Daewoong Pharmaceutical Co., Ltd Competitors

KOSE:A185750

₩1.2t

KOSDAQ:A214370

₩1.1t

KOSDAQ:A237690

₩1.7t

KOSE:A003090

₩854.6b

Price History & Performance

Recent News & Updates

Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)

There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price

Price target increased by 7.8% to ₩190,000

Price target increased by 11% to ₩176,250

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 15%

Recent updates

Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)

There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price

Price target increased by 7.8% to ₩190,000

Price target increased by 11% to ₩176,250

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 19%

Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate

Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-In-Class PRS Inhibitor, Bersiporocin

Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings

Investor sentiment improves as stock rises 19%

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Consensus EPS estimates increase by 25%

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Upcoming dividend of ₩600 per share at 0.5% yield

Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-Dose Administration of Nabota

Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy

Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

Price target decreased by 7.5% to ₩171,083

Daewoong Pharmaceutical Obtains Approval for SGLT2i + Metformin Combination Drug Envlomet

New minor risk - Shareholder dilution

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023

Full year 2022 earnings released: EPS: ₩3,816 (vs ₩2,227 in FY 2021)

Now 20% undervalued after recent price drop

Price target decreased by 7.4% to ₩205,714

Investor sentiment deteriorates as stock falls 18%

Daewoong Pharmaceutical Begins the First Administration of Bersiporocin

Daewoong Pharmaceutical Co.,Ltd Submits NDA for Its Global New Drug Fexuclue in 11 Countries, Only 1 Year After Approval in Korea

Consensus forecasts updated

Upcoming dividend of ₩600 per share

Daewoong Pharmaceutical Announces Success in Developing New Antidiabetic Medication

Now 20% undervalued after recent price drop

Less than half of directors are independent

Daewoong Pharmaceutical Announces Phase 3 Clinical Trial Results of New Diabetes Treatment Enavogliflozin

Investor sentiment improved over the past week

Price target increased to ₩235,714

Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-In-Class Irreversible Oral Dual Acting Inhibitor for Autoimmune Diseases

Price target increased to ₩235,000

Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug

Investor sentiment improved over the past week

Less than half of directors are independent

Daewoong Pharmaceutical Submits NDA for its Global New Drug Fexuclue Tablets to the Philippines

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Daewoong pharmaceutical Co.,Ltd Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy

Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug

Upcoming dividend of ₩600 per share

Price target increased to ₩199,000

Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes

Daewoong Pharmaceutical of South Korea Announces PRS-Inhibitor for Idiopathic Pulmonary Fibrosis Shows Promising Result in Early Stage Clinical Test

First quarter 2021 earnings released: ₩2,139 loss per share (vs ₩65.00 profit in 1Q 2020)

Price target increased to ₩147,143

Evolus, Inc. and Daewoong Pharmaceuticals Co., Ltd. Enter into Settlement Agreement

Full year 2020 earnings released: EPS ₩1,196 (vs ₩2,132 in FY 2019)

Daewoong pharmaceutical Co.,Ltd., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩121,000

Price target raised to ₩126,625

New 90-day high: ₩119,000